Fisher Asset Management
LTRN icon

Fisher Asset Management’s Lantern Pharma LTRN Stock Holding History

Fisher Asset Management’s Portfolio LTRN Stock Details LTRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-10,000
Closed -$46.7K – 975
2024
Q2 		$46.7K Buy
+10,000
New +$60.1K ﹤0.01% 974

Other funds holding LTRN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $33.6B AUM 31.03% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RAM
Redmond Asset Management Henrico, Virginia $401M AUM 14.95% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Fisher Asset Management's LTRN Position: Q3 2024 in Review

Fisher Asset Management sold out of Lantern Pharma (LTRN) in Q3 2024, closing a stake of 10,000 shares — an estimated $46.7K sold.

Fisher Asset Management first reported a position in LTRN in Q2 2024 and held it in 1 quarter. The position peaked at $46.7K in Q2 2024. 31 funds tracked by Wall St. Rank hold LTRN as of Q3 2024.

  • Fisher Asset Management reported no remaining Lantern Pharma position as of Q3 2024 after selling out during the quarter.
  • Fisher Asset Management sold 10,000 Lantern Pharma shares in Q3 2024, an estimated $46.7K.
  • Fisher Asset Management first reported a position in Lantern Pharma in Q2 2024 and held it in 1 quarter.
  • Fisher Asset Management's Lantern Pharma position peaked at $46.7K in Q2 2024.
  • 31 funds tracked by Wall St. Rank held Lantern Pharma as of Q3 2024.

Based on Fisher Asset Management's 13F filing for Q3 2024, filed 12 Nov 2024.